Opthea (ASX:OPT) completed its drug product process performance qualification campaign for its sozinibercept drug candidate to treat wet age-related macular degeneration, demonstrating its ability to consistently manufacture the candidate at a commercial scale, according to a Wednesday Australian bourse filing.
The campaign consisted of the production of three consecutive commercial-scale drug product batches.
This was required to further validate its manufacturing process in preparation for a potential biologics license application filing, as well as the commercialization of sozinibercept, in the first half of 2026.
The firm's shares fell 5% in early trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。